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Abstract
Background: Syndecan-1 is a transmembrane proteoglycan with important roles in cell-cell and cell-
extracellular matrix adhesion and as a growth factor co-receptor. Syndecan-1 is highly expressed by
normal epithelial cells and loss of expression has been associated with epithelial-mesenchymal transition
and the transformed phenotype. Loss of epithelial syndecan-1 has been reported in human colorectal
adenocarcinomas, but whether this has prognostic significance remains undecided. Here we have
examined syndecan-1 expression and its potential prognostic value with reference to a clinically annotated
tissue microarray for human colon adenocarcinomas.
Methods:  Syndecan-1 expression was examined by immunohistochemistry of a tissue microarray
containing cores from 158 colorectal adenocarcinomas and 15 adenomas linked to a Cleveland Clinic, IRB-
approved database with a mean clinical follow-up of 38 months. The Kaplan-Meier method was used to
analyze the relationship between syndecan-1 expression and patient survival. Potential correlations
between syndecan-1 expression and the candidate prognostic biomarker fascin were examined.
Results:  Syndecan-1 is expressed at the basolateral borders of normal colonic epithelial cells. On
adenocarcinoma cells, syndecan-1 was present around cell membranes and in cytoplasm. In 87% of
adenocarcinomas, syndecan-1 was decreased or absent; only 13% of patients had stained for syndecan-1
on more than 75% of tumor cells. Decreased syndecan-1 correlated with a higher TNM stage and lymph
node metastasis and was more common in males (p = 0.042), but was not associated with age, tumor
location or Ki67 index. Reduced tumor syndecan-1 staining also correlated with upregulation of stromal
fascin (p = 0.016). Stromal syndecan-1 was observed in 16.6% of tumors. There was no difference in
survival between patients with low or high levels of either tumor or stromal syndecan-1.
Conclusion:  Syndecan-1 immunoreactivity was decreased in the majority of human colon
adenocarcinomas in correlation with TNM stage and metastasis to local lymph nodes. In a small fraction
of adenocarcinomas, syndecan-1 was upregulated in the local stroma. Syndecan-1 expression status did
not correlate with patient survival outcomes. Combined analysis of syndecan-1 in relation to a potential
prognostic biomarker, fascin, identified that loss of tumor syndecan-1 correlated significantly with strong
stromal fascin staining.
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Background
Syndecans are a conserved family of transmembrane
heparan sulfate proteoglycan receptors that participate in
cell-cell and cell-extracellular matrix adhesion and the
actions of peptide growth factors in normal tissues [1,2].
In land vertebrates, the syndecan gene family contains 4
members of which syndecan-4 is the most widely
expressed [3]. Syndecan-1 is expressed predominantly in
epithelia, but is also found on fibroblasts, myoblasts and
differentiating B cells and is up-regulated in multiple mye-
loma [1,2,4]. Syndecan-1 null mice are resistant to Wnt1-
activated mammary tumors and carcinogen-induced
tumor development and have increased susceptibility to
allergen-induced airway inflammation [5-7]. Syndecan-1
null mice are also defective in repair of corneal and epi-
dermal wounds [8,9]. Overall, these data demonstrate
important contributions of syndecan-1 in the regulation
of epithelial homeostasis, proliferation and migration.
In cell culture models, E-cadherin dependent loss of cell-
surface syndecan-1 is associated with epithelial-mesen-
chymal transition and the epithelial phenotype is restored
by over-expression of syndecan-1 [10-12]. Syndecan-1
over-expression also inhibits cell invasion into collagen
gels [13]. Similarly, malignant transformation of Caco-2
epithelial cells is associated with loss of syndecan-1 [14].
Although these studies implicated tumor suppressor roles
of syndecan-1, the relationship of syndecan-1 expression
to tumor progression or clinical outcomes in human car-
cinomas has proved to be more complex. Thus, in gastric
cancers, tumor cell expression of syndecan-1 has been cor-
related with patient survival and the loss of syndecan-1
with a poor prognosis [15,16]. A fraction of patients have
abnormal up-regulation of syndecan-1 on stromal cells in
the vicinity of the tumor, and this also correlates with
poor prognosis [16]. Similar observations have been
made in other carcinomas, for example [17-20]. However,
for pancreatic and breast carcinomas there are conflicting
reports that increased syndecan-1 expression correlates
with a poor prognosis or resistance to chemotherapy [21-
24]. These complex data point to a need for continuing
assessment of syndecan-1 status in relation to the clinico-
pathological characteristics of carcinomas from different
tissue sources.
Colorectal carcinoma is the third most common form of
cancer in both men and women in the USA and Europe. It
remains a major cause of cancer mortality, with a 5 year
survival rate of 60%, and its incidence is expected to
increase in association with the ageing of western popula-
tions [25]. The major therapeutic approach is surgical
resection and there is an urgent need to identify new
biomarkers to improve strategies for adjuvant therapies or
post-operative monitoring. We and others have recently
demonstrated that expression of the actin-bundling pro-
tein, fascin, has prognostic significance in colorectal ade-
nocarcinoma [26,27]. In non-transformed cells,
syndecan-1 acts as a transducer of extracellular matrix cues
that regulate the organization of actin and fascin in lamel-
lipodia [28]. It has been reported that syndecan-1 expres-
sion is decreased in colorectal adenocarcinomas in
comparison to adenomas and the normal tissue [29-31],
and that reduced expression correlates with the incidence
of local metastases [30]. Increased levels of syndecan-1 in
the local stroma have also been described [32]. However,
the prognostic relevance of changes in syndecan-1 expres-
sion in colorectal carcinoma remains unclear from the
published studies [30,31]. In view of the health burden
imposed by colorectal carcinoma, we examined a tissue
microarray of clinically annotated colorectal carcinoma
specimens and report on our analysis of epithelial or stro-
mal syndecan-1 expression in relation to patient out-
comes and the expression of the recently identified
potential biomarker, fascin.
Methods
Immunohistochemical staining
The tissue microarray (TMA) was custom built and vali-
dated as described [26]. The TMA contained a total of 374
cores, from 14 normal colonic epithelia, 15 adenomas
and 158 colorectal adenocarcinomas that were diagnosed
at The Cleveland Clinic between 1993 and 1999. The
majority of the adenocarcinomas were moderately differ-
entiated and six were poorly-differentiated. Tumors were
classified according to standard TNM staging guidelines
[33]. To minimize sampling errors, two separate large
diameter (1.5 mm diameter) tissue cores of each adeno-
carcinoma were included in the array, totaling a surface
area of 3.5 mm2 per case. The areas covered by these cores
included the edge of each tumor. Each separate tissue core
was assigned a unique TMA location number that was
linked to a CCF Institutional Review Board-approved
(IRB-5085) database containing a mean 38 months of
clinical follow-up. From the 316 cores, 131 of the 158
adenocarcinoma samples were available for scoring.
Immunohistochemistry was carried out using an auto-
mated Ventana Benchmark system as described [26].
Briefly, a 4-μm thick unstained section of each TMA was
placed onto an electrostatically charged glass slide and
baked for tissue adherence. Slides were pretreated with the
recommended pretreatment solution (Ventana) for tissue
deparaffinization and antigen retrieval. Slides were incu-
bated with clone B-A38 mouse monoclonal antibody to
human syndecan-1/CD138 (Serotec) at 1: 100 dilution, a
secondary biotinylated antibody and a streptavidin
amplification step. Antigen detection was carried out by
peroxidase/3,3'-diaminobenzidine reaction. CD138
immunoreactivity was scored by two independent observ-
ers in a blinded procedure without prior knowledge of the
clinical information and was classified for the staining ofBMC Cancer 2008, 8:185 http://www.biomedcentral.com/1471-2407/8/185
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the tumor or the stromal cells, in either the tumor or the
stroma, as 0 (less than 5% of cells); 1+ (5% – 25% of
cells); 2+ (25% – 75% of cells), or 3+ (more than 75% of
cells). Positive staining in plasma cells served as an inter-
nal positive control for syndecan-1. Stromal positivity was
evaluated for the non-plasma cell stromal elements. In the
less than 10% of cases where the opinions of the two eval-
uators differed, a consensus agreement was reached by re-
review of the slides, thorough discussion and if necessary
taking the average score. The fascin staining and scoring
method has been described [26].
Statistical analysis
The expression level of CD138 in relation to clinicopatho-
logical factors, Ki67 index, or fascin expression was ana-
lyzed using chi2. Overall survival was defined as that from
the date of the operation to the date of death due to can-
cer. The Kaplan-Meier method was used to determine the
probability of survival and data was analyzed with the log-
rank test. StatView for Windows version 5 software (SAS
Institute, Cary, NC) was used for the analysis. Median sur-
vival times were calculated using Dr. SPSS II for Windows
version 11.0.1J (SPSS Japan Inc., Tokyo, JAPAN). In the
analyses, a p value of <0.05 was considered significant.
Results
Syndecan-1 expression in colon adenocarcinomas
In the normal colon, syndecan-1 was expressed around
the basolateral membrane of the normal columnar epi-
thelium and in plasma cells. Syndecan-1 staining was
absent from the stroma (Fig. 1a). This staining pattern was
unchanged in adenomas (not shown). In contrast, in the
majority of the adenocarcinomas, syndecan-1 staining
was decreased or absent (Fig. 1b,c). Loss of syndecan-1
from tumor cells was most pronounced in the most
poorly differentiated tumors (Fig. 1c). Out of 131
patients, in 65 cases syndecan-1 was expressed on less
than 25% of the tumor cells, and in 49 cases between 25%
to 75% of tumor cells were stained. Only in 17 cases did
more than 75% of the tumor cells stain for syndecan-1
(Table 1). On the tumor cells, syndecan-1 was localized
around the entire cell membrane and in many cells
appeared to be cytoplasmically located (Fig. 1b). The TMA
cores included the tumor borders, however we did not
detect any consistent specific association of syndecan-1
immunoreactivity with tumor edges.
In contrast to the normal stroma that was typically nega-
tive for syndecan-1 (Fig. 1a), some tumor specimens,
without or with tumor expression of syndecan-1, had pos-
itive staining for syndecan-1 in the stroma. In total, 16.6%
of the tumors had some level of stromal syndecan-1 stain-
ing: 8.8% of tumors had weak expression and 7.9% had
moderate or strong expression. Fig. 1d shows an example
of a tumor with moderate tumor syndecan-1 and strong
stromal staining for syndecan-1.
Relationship between syndecan-1 status, 
clinicopathological characteristics and clinical prognosis
The correlation between syndecan-1 immunoreactivity
and several clinico-pathological characteristics was inves-
tigated. The TMA had been previously validated as repre-
sentative for traditional prognostic variables of colorectal
cancer, including the correlation of tumor stage and
metastasis to local lymph nodes with patient survival
[26]. The incidence of low expression of syndecan-1 was
significantly higher in males (p = 0.042), in tumors of
higher TNM stage (p = 0.045), and in patients positive for
Table 1: Relationship between syndecan-1 immunoreactivity and clinicopathological characteristics
Syndecan-1 staining (percentage of tumors in brackets)
01 +2 +3 +
n = 38 (29%) n = 27 (21%) n = 49 (37%) n = 17 (13%) p
Variable
Age 0.651
<65 yrs 16 (42.1) 12 (44.4) 17 (34.7) 6 (35.3)
≥ 65 yrs 22 (57.9) 15 (55.6) 32 (65.3) 11 (64.7)
Gender 0.042*
Male 24 (63.2) 22 (81.5) 23 (46.9) 10 (58.8)
Female 14 (36.8) 5 (18.5) 26 (53.1) 7 (41.2)
Stage 0.045*
I/II 14 (36.8) 13 (48.1) 33 (67.3) 9 (52.9)
III/IV 24 (63.2) 14 (51.9) 16 (32.7) 8 (47.1)
Lymph node metastasis 0.017*
negative 16 (42.1) 14 (51.9) 36 (73.5) 12 (70.6)
positive 22 (57.9) 13 (48.1) 13 (26.5) 5 (29.4)
Location 0.380
Proximal 13 (34.2) 9 (33.3) 13 (26.5) 2 (11.8)
Distal 25 (65.8) 18 (66.7) 36 (73.5) 15 (88.2)BMC Cancer 2008, 8:185 http://www.biomedcentral.com/1471-2407/8/185
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lymph node metastasis (p = 0.017) (Table 1). There was
no correlation between syndecan-1 status and tumor loca-
tion (Table 1). In cumulative survival analysis, there was
no difference of prognosis associated with either low or
high syndecan-1 on the tumor cells or in the stroma. This
result was obtained when each scoring category was exam-
ined individually, or when the samples were compared as
two groups (low, corresponding to 0 and 1+ scores versus
high, corresponding to 2+ and 3+ scores) using the Kap-
lan-Meier method. This result was obtained when the
analysis for tumor syndecan-1 was applied either to the
whole group of stage I-IV cases (p = 0.398), or to the stage
III-IV group alone (p = 0.843) (Fig. 2; for clarity of presen-
tation only the data for the low vs. high scoring groupings
is shown). We also examined the 5 year survival rate and
median survival times for each of the tumor syndecan-1
scoring categories. Again, there was no significant differ-
ence in survival between the scoring categories (Table 2).
Relationship between syndecan-1 status and other 
biomarkers
We had previously examined the same tissue microarray
set of tumors for fascin and Ki67 immunostaining. Posi-
tive fascin expression correlated with a poor prognosis in
stage III/IV patients and a high Ki67 index correlated with
TNM stage [26]. Because syndecan-1 and fascin are com-
ponents of the same pathway that regulates cell motility in
non-transformed cells, the syndecan-1 stained samples
were evaluated for possible correlations with either fascin
status or Ki67 index, with reference to our previously pub-
lished datasets for these markers. There was no correlation
between low expression of syndecan-1 and high fascin
expression in tumor cells, either in the whole group or the
stage III/IV patients alone. Neither tumor nor stromal syn-
decan-1 correlated with Ki67 index (data not shown).
However, reduced tumor cell staining for syndecan-1 cor-
related significantly with strong stromal staining for fascin
Expression of syndecan-1 in normal colonic epithelium and colon adenocarcinomas Figure 1
Expression of syndecan-1 in normal colonic epithelium and colon adenocarcinomas. a, immunohistochemical stain-
ing for syndecan-1 in normal colon. b-c, syndecan-1 staining of colon adenocarcinomas is lost in correlation with tumor differ-
entiation status. d, example of a moderately differentiated adenocarcinoma with strong stromal staining for syndecan-1 and 
moderate staining of the tumor. e, f, contiguous sections of the same tumor stained for syndecan-1, (e), or fascin, (f), demon-
strating strong staining for fascin in the stroma (arrowed). The tumor cells are negative for fascin and syndecan-1. Isolated 
strongly fascin positive cells correspond to dendritic and vascular endothelial cells and provideinternal positive controls for the 
fascin staining.
a. Normal colon b. Moderately differentiated
adenocarcinoma,
epithelial syndecan-1
c. Poorly differentiated
adenocarcinoma
d. Moderately differentiated
adenocarcinoma,
epithelial and stromal syndecan-1
x200 x200
x200
x200
e. Moderately differentiated
adenocarcinoma,
syndecan-1 
f. Moderately differentiated
adenocarcinoma,
fascin 
x200 x200BMC Cancer 2008, 8:185 http://www.biomedcentral.com/1471-2407/8/185
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(p = 0.016; Table 3). An example of a syndecan-1 negative
tumor with strong stromal staining for fascin is shown in
Fig. 1e and 1f.
Discussion
The results of our study demonstrate that the loss of
expression of syndecan-1 from colonic epithelial cells in
colorectal adenocarcinomas correlates with tumor TNM
stage and incidence of local lymph node metastasis but
nevertheless does not correlate statistically with patient
survival. Two previous studies reached conflicting conclu-
sions on whether reduced syndecan-1 correlated with
decreased patient survivial [30,31]. Our data are in agree-
ment with the study of Lundin et al. [31]. We also exam-
ined the relationship between syndecan-1 and a recently
identified novel independent prognostic factor for color-
ectal carcinoma, fascin [26,27]. A novel significant corre-
lation between decreased syndecan-1 staining on tumor
cells and increased stromal fascin staining was detected.
Our findings from a large, clinically annotated tissue
microarray of colorectal carcinoma specimens add to the
body of evidence that loss of epithelial syndecan-1 is a
general feature of carcinoma progression. In agreement
with other analyses of colorectal carcinoma, loss of epi-
thelial syndecan-1 correlated with tumor TNM stage [29-
31] and incidence of metastases to local lymph nodes
[30,31]. Epithelial to mesenchymal transition (EMT) is a
major process in tumor progression and loss of expression
of syndecan-1 is well established to regulate aspects of
EMT [1,10,11]. Thus the loss of epithelial syndecan-1 is
likely permissive for development of higher stage, more
biologically aggressive tumors. The correlation of loss of
syndecan-1 with male gender documented in our study
(Table 1) has not been observed in previous studies and
the biological significance of this observation is unclear at
this time. Loss of syndecan-1 did not correlate with tumor
location. Thus there does not appear to be a close biolog-
ical relationship between syndecan-1 status and microsat-
ellite instability, which is strongly associated with tumor
location in the proximal colon [34].
In a minority of the specimens (16.6%) stromal staining
for syndecan-1 was increased in comparison to the nor-
mal tissue. This percentage is markedly lower than in one
prior report, where stromal syndecan-1 immunoreactivity
was observed in 58% of specimens [31], but is consistent
with an analysis of micro-dissected tissues that identified
7.4% of specimens to have elevated syndecan-1 content,
largely due to stromal expression [32]. By comparing in
situ hybridization with immunohistochemistry, the latter
study demonstrated that stromal syndecan-1 immunore-
activity is due to expression of the SDCN1 transcript in a
Table 2: Relationship between tumor syndecan-1 status and 
patient 5 year and median survival
Syndecan-1
Scoring
5 yr survival
rate (%)
Median 
survival (months)
95% CI
0 38.6 43 21–97
1+ 47.7 49 16–82
2+ 52.0 83 45–121
3+ 43.7 57 5–109
Relationship of tumor syndecan-1 status to patient survival Figure 2
Relationship of tumor syndecan-1 status to patient 
survival. The Kaplan-Meier survival curves demonstrate that 
low (0 or +1 staining) or high (+2 or +3 staining) syndecan-1 
staining of the tumors did not correlate with overall survival, 
either in the whole study population (a) or the stage III/IV 
tumors (b).
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Table 3: Loss of tumor cell syndecan-1 correlates with high 
stromal fascin staining
Fascin in stroma 
Tumor CD138 (0/2+) (3+)
CD138 (0/1+) 55 10
CD138 (2+/3+) 64 2
p value nsd 0.0164BMC Cancer 2008, 8:185 http://www.biomedcentral.com/1471-2407/8/185
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stromal cell population, likely myofibroblasts [32]. It is
likely that stromal syndecan-1 has impact on the tumor
microenvironment by alterations to the retention of
heparin binding growth factors and extracellular matrix
components in the vicinity of the tumor. These factors
have been proposed to facilitate tumor cell invasion and,
in general, the tumor stroma has an important role in can-
cer development [1,4,35]. Nevertheless, from the current
analysis, the presence of stromal syndecan-1 did not cor-
relate with a more biologically aggressive tumor pheno-
type or altered patient survival outcomes. A previous
analysis is consistent with this conclusion [31]. We
observed a wide variation of staining intensity for stromal
syndecan-1 and also variations in the distribution of
staining, which tended to be patchy within limited areas
of the stroma. We speculate that expression of stromal
syndecan-1 might be transient and reflective of short-term
phenotypic changes in stromal myofibroblasts.
Although our data did not support syndecan-1 status as an
independent prognostic factor in colorectal carcinoma, it
was of interest to examine whether additional informa-
tion could be obtained from analyzing syndecan-1 status
in combination with another candidate biomarker. We
selected fascin for this analysis, because syndecan-1 is a
functionally significant regulator of the cytoskeletal
organization of actin and fascin in several normal cell
types [28,36]. Moreover, fascin is absent from normal
colonic epithelium and its upregulation in colorectal ade-
nocarcinomas correlates with poor prognosis [26,27]. In
the normal stroma, fascin is detected at low levels in
fibroblasts and at higher levels in dendritic cells and vas-
cular endothelial cells. These studies also uncovered that
stromal fascin is increased in at least 47% of tumor speci-
mens, irrespective of the fascin status of the tumor
[26,37]. From study of contiguous sections of the same
Cleveland Clinic colorectal tissue microarray specimen set
stained for syndecan-1, we identified that loss of tumor
cell syndecan-1 did not correlate with the upregulation of
fascin in clinically aggressive adenocarcinomas. However,
loss of syndecan-1 immunoreactivity of the tumor did
correlate significantly with strong stromal fascin staining.
This novel finding brings further support to the idea that
upregulation of stromal fascin may represent an aspect of
the host-tumor interaction. The altered adhesive and
motility properties of both tumor cells and adjacent stro-
mal cells may jointly contribute to tumor progression.
Future studies of independent datasets will be needed to
validate the statistical as well as the clinical significance of
the combined biomarker data.
We also identified that, in the tumors where stromal syn-
decan-1 was elevated, stromal syndecan-1 frequently
overlapped with areas of increased stromal fascin (Fig.
1d). However, the fractions of positive specimens (16.6%
for stromal syndecan-1 and 47% for stromal fascin) were
very different. We infer that either the two molecules are
under separate regulation, or that fascin is expressed by
multiple cell types within the stroma. Abnormal expres-
sion of fascin by foci of stromal fibroblasts has also been
observed in idiopathic pulmonary fibrosis [38]. We spec-
ulate that for stromal cells in which both syndecan-1 and
fascin are upregulated, syndecan-1 could provide pro-
migratory cues through its intracellular regulation of fas-
cin that promotes formation of lamellipodia [28]. On the
basis of the small total number of cases that were positive
for stromal syndecan-1 in our dataset, the observation of
co-staining for stromal syndecan-1 and fascin did not
have statistical significance.
Conclusion
Syndecan-1 immunoreactivity is decreased in the majority
of human colon adenocarcinomas in correlation with
TNM stage and local lymph node metastasis. A small frac-
tion of adenocarcinomas have increased syndecan-1 stain-
ing in the local stroma. Syndecan-1 status does not
correlate with patient survival outcomes. Combined anal-
ysis of syndecan-1 in relation to a recently identified
potential prognostic biomarker, fascin, identified a subset
of tumors in which loss of tumor cell syndecan-1 corre-
lates significantly with up-regulation stromal of fascin.
These findings may assist improved biomarker identifica-
tion of aggressive forms of colorectal adenocarcinoma.
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